Picture loading failed.

Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-095-1mg 1mg 3090
GMP-Bios-ab-095-10mg 10mg Inquiry
GMP-Bios-ab-095-100mg 100mg Inquiry
GMP-Bios-ab-095-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody
INN Name Carotuximab
TargetENG
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesNational Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedFallopian tube cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Haemangiosarcoma;Choriocarcinoma;Glioblastoma;Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Breast cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Colorectal cancer;Precursor B-cell lymphoblastic leukaemia-lymphoma;Wet age-related macular degeneration
Development Techna